Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 37 articles:
HTML format
Text format



Single Articles


    November 2017
  1. KAKUTA Y, Kinouchi Y, Shimosegawa T
    Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
    J Gastroenterol. 2017 Nov 30. pii: 10.1007/s00535-017-1416.
    PubMed     Text format     Abstract available


    October 2017
  2. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1399.
    PubMed     Text format     Abstract available


    September 2017
  3. HANAOKA M, Ishikawa T, Ishiguro M, Tokura M, et al
    Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia.
    J Gastroenterol. 2017 Sep 7. doi: 10.1007/s00535-017-1387.
    PubMed     Text format     Abstract available


  4. UCHINO M, Ikeuchi H, Sugita A, Futami K, et al
    Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study.
    J Gastroenterol. 2017 Sep 7. doi: 10.1007/s00535-017-1389.
    PubMed     Text format     Abstract available


    August 2017
  5. NISHINO K, Nishida A, Inoue R, Kawada Y, et al
    Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease.
    J Gastroenterol. 2017 Aug 29. doi: 10.1007/s00535-017-1384.
    PubMed     Text format     Abstract available


  6. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Aug 4. doi: 10.1007/s00535-017-1376.
    PubMed     Text format     Abstract available


    June 2017
  7. KOBAYASHI T, Matsuoka K, Yokoyama Y, Nakamura T, et al
    A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.
    J Gastroenterol. 2017 Jun 8. doi: 10.1007/s00535-017-1356.
    PubMed     Text format     Abstract available


    May 2017
  8. IHARA S, Hirata Y, Koike K
    TGF-beta in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.
    J Gastroenterol. 2017 May 22. doi: 10.1007/s00535-017-1350.
    PubMed     Text format     Abstract available


  9. QIU Y, Chen BL, Mao R, Zhang SH, et al
    Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease.
    J Gastroenterol. 2017;52:535-554.
    PubMed     Text format     Abstract available


  10. RIMOLA J, Alvarez-Cofino A, Perez-Jeldres T, Ayuso C, et al
    Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease.
    J Gastroenterol. 2017;52:585-593.
    PubMed     Text format     Abstract available


  11. BUISSON A, Hordonneau C, Goutte M, Bommelaer G, et al
    What score should be used for evaluation of Crohn's disease severity using magnetic resonance imaging?
    J Gastroenterol. 2017;52:652-653.
    PubMed     Text format    


    April 2017
  12. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Apr 12. doi: 10.1007/s00535-017-1340.
    PubMed     Text format    


    March 2017
  13. HIBI T, Imai Y, Senoo A, Ohta K, et al
    Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    J Gastroenterol. 2017 Mar 21. doi: 10.1007/s00535-017-1326.
    PubMed     Text format     Abstract available


  14. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Mar 20. doi: 10.1007/s00535-017-1325.
    PubMed     Text format     Abstract available


    February 2017
  15. ARAKI M, Shinzaki S, Yamada T, Arimitsu S, et al
    Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease.
    J Gastroenterol. 2017 Feb 6. doi: 10.1007/s00535-017-1313.
    PubMed     Text format     Abstract available


    January 2017
  16. SUN M, Wu W, Liu Z, Cong Y, et al
    Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases.
    J Gastroenterol. 2017;52:1-8.
    PubMed     Text format     Abstract available


    November 2016
  17. IBORRA M, Gisbert JP, Bosca-Watts MM, Lopez-Garcia A, et al
    Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients.
    J Gastroenterol. 2016.
    PubMed     Text format    


  18. CHAN HC, Ng SC
    Emerging biologics in inflammatory bowel disease.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  19. NISHIDA A, Imaeda H, Ohno M, Inatomi O, et al
    Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  20. IBORRA M, Perez-Gisbert J, Bosca-Watts MM, Lopez-Garcia A, et al
    Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  21. MARTELLI L, Olivera P, Roblin X, Attar A, et al
    Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  22. UENO F, Nakayama Y, Hagiwara E, Kurimoto S, et al
    Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  23. KEDIA S, Rampal R, Paul J, Ahuja V, et al
    Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India.
    J Gastroenterol. 2016;51:660-71.
    PubMed     Text format     Abstract available


    June 2016
  24. IBOSHI Y, Nakamura K, Fukaura K, Iwasa T, et al
    Erratum to: "Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis".
    J Gastroenterol. 2016.
    PubMed     Text format    


  25. MUSCI JO, Cornish JS, Dabritz J
    Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.
    J Gastroenterol. 2016;51:531-47.
    PubMed     Text format     Abstract available


    May 2016
  26. IBOSHI Y, Nakamura K, Fukaura K, Iwasa T, et al
    Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  27. SUGIMOTO S, Naganuma M, Kanai T
    Indole compounds may be promising medicines for ulcerative colitis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  28. KUWAHARA E, Murakami Y, Nakamura T, Inoue N, et al
    Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  29. WILSON JC, Furlano RI, Jick SS, Meier CR, et al
    A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  30. IKHTAIRE S, Shajib MS, Reinisch W, Khan WI, et al
    Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  31. BETTENWORTH D, Lopez R, Hindryckx P, Levesque BG, et al
    Heterogeneity in endoscopic treatment of Crohn's disease-associated strictures: An international inflammatory bowel disease specialist survey.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  32. ASADA A, Nishida A, Shioya M, Imaeda H, et al
    NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  33. FUYUNO Y, Yamazaki K, Takahashi A, Esaki M, et al
    Genetic characteristics of inflammatory bowel disease in a Japanese population.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  34. KOBAYASHI T, Suzuki Y, Motoya S, Hirai F, et al
    First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  35. OKAMOTO R, Watanabe M
    Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  36. NIIKURA R, Yasunaga H, Yamaji Y, Horiguchi H, et al
    Factors affecting in-hospital mortality in patients with lower gastrointestinal tract bleeding: a retrospective study using a national database in Japan.
    J Gastroenterol. 2015;50:533-40.
    PubMed     Text format     Abstract available


    April 2015
  37. KAWAGUCHI T, Mori M, Saito K, Suga Y, et al
    Food antigen-induced immune responses in Crohn's disease patients and experimental colitis mice.
    J Gastroenterol. 2015;50:394-405.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: